Teva Pharmaceutical Industries Limited Expected to Post Q3 2025 Earnings of $0.62 Per Share (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research report issued to clients and investors on Wednesday, May 1st. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.62 for the quarter, up from their previous forecast of $0.61. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.78 EPS and FY2025 earnings at $2.42 EPS.

A number of other brokerages have also commented on TEVA. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $12.00 to $19.00 in a research note on Monday, February 12th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a research report on Friday, March 8th. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and raised their price target for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Finally, Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Down 0.2 %

Shares of Teva Pharmaceutical Industries stock traded down $0.03 on Friday, hitting $14.05. The company had a trading volume of 3,021,096 shares, compared to its average volume of 10,411,227. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. Teva Pharmaceutical Industries has a twelve month low of $7.09 and a twelve month high of $14.47. The firm has a market capitalization of $15.75 billion, a P/E ratio of -29.95, a P/E/G ratio of 1.67 and a beta of 1.04. The stock has a 50-day moving average of $13.59 and a 200-day moving average of $11.53.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $3.97 billion.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Assenagon Asset Management S.A. increased its stake in shares of Teva Pharmaceutical Industries by 705.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock worth $6,051,000 after purchasing an additional 507,568 shares during the period. Los Angeles Capital Management LLC acquired a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $3,000,000. SG Americas Securities LLC raised its position in shares of Teva Pharmaceutical Industries by 31.7% during the fourth quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock worth $5,689,000 after purchasing an additional 131,043 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Teva Pharmaceutical Industries by 42.2% in the third quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after buying an additional 102,261 shares during the period. Finally, Gateway Investment Advisers LLC grew its holdings in shares of Teva Pharmaceutical Industries by 28.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after buying an additional 9,312 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders sold a total of 358,972 shares of company stock valued at $4,739,820 in the last quarter. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.